Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes | Zendy

Khalaf Kridin | Zendy; Richard N. Bergman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes

Author(s) -

Khalaf Kridin,

Richard N. Bergman

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.2352

Subject(s) - medicine , linagliptin , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , bullous pemphigoid , dipeptidyl peptidase 4 , type 2 diabetes , retrospective cohort study , metformin , gastroenterology , endocrinology , immunology , antibody

The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase 4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of developing BP during treatment with new DPP-4 inhibitor agents like linagliptin is yet to be established. The clinical features and the prognostic outcomes of patients with DPP-4 inhibitor-associated BP are yet to be established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research